David A. Siegel An2 Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 269,600 shares of ANTX stock, worth $326,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
269,600
Previous 445,004
39.42%
Holding current value
$326,216
Previous $605,000
52.89%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ANTX
# of Institutions
39Shares Held
7.6MCall Options Held
0Put Options Held
0-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.73 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.25 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY583KShares$705,1510.62% of portfolio
-
Stonepine Capital Management, LLC Bend, OR544KShares$658,8370.57% of portfolio
-
Landscape Capital Management, L.L.C.495KShares$599,4290.05% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $23.5M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...